Daiichi Sankyo Statement on Passing of José Baselga, MD, PhD



Tokyo, Japan (March 22, 2021) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) issued the following statement today from Sunao Manabe, President and CEO of Daiichi Sankyo:                                                                                                                    

“All of us at Daiichi Sankyo are deeply saddened by the news of the passing of Dr. José Baselga, a brilliant scientist, cancer researcher, physician, patient advocate, mentor and friend to many. We at Daiichi Sankyo were fortunate to collaborate and work closely with José since 2016, when he became the primary investigator for one of our leading antibody drug conjugates, and then over the past two years as a result of our collaboration with AstraZeneca. We were privileged to join forces with him to advance science for patients with cancer, and we will continue this important work in his memory. Our heartfelt condolences go out to his family, friends, and all those whose lives have been touched by José.”

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: https://www.daiichisankyo.com/.